Vima Therapeutics

Single-Patient EA Policies/Criteria Vima Therapeutics (Vima) is focused on developing safe and effective treatments for patients with movement disorders. The development process of investigational medications (e.g., possible treatments) requires extensive evaluation of their safety and efficacy through clinical studies. We are working closely with scientists, physicians, clinical study site teams, advocacy groups, patients and their families to conduct our clinical studies efficiently and effectively. When completed, data from these studies will be provided to regulators (i.e., FDA, EMA, or similar regulatory agencies) to assess and grant regulatory approval and therefore, enable equitable and sustainable access for patients. We understand that patients and their families may be interested in accessing our investigational medications outside of the clinical study setting and prior to regulatory approval through an expanded access program (a.k.a. “early access” or “compassionate use”). Vima does not currently offer access to their investigational medications through an expanded access program. At this time, a clinical study is the only way to access potential medications currently under development at Vima. For more information, please contact expandedaccess@vimatx.com . Vima regularly reviews its policies to ensure conformity with applicable laws and regulations and reserves the right to revise this policy at any time.